AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 JUL 5 - (NewsRx.com & NewsRx.net) -- Matritech, Inc., (MZT), a developer of protein-based diagnostic products for the early detection of cancer, and Wampole Laboratories, LLC, a wholly owned subsidiary of Inverness Medical Innovations, Inc., announced an agreement for the distribution of Matritech's NMP22 Test Kit.
Under the terms of the agreement, Wampole will receive exclusive rights to distribute the NMP22 ELISA (Enzyme Linked Immunosorbent Assay) Test Kit to hospitals and clinical reference laboratories in the United States. Matritech's own sales force will continue to sell the NMP22 BladderChek Test directly to urologists in their offices.
"Wampole's proven ability to market and distribute products to hospitals and reference laboratories and their leadership position in ELISA testing made them an obvious choice for marketing our NMP22 Test Kit. Given the synergistic relationship between the NMP22 BladderChek Test and the NMP22 Test Kit, we have seen an increase in the number of lab tests being performed as the number of NMP22 BladderChek Tests has risen. As our own sales force continues to increase sales to the urologist, we ...
Source: HighBeam Research, Companies sign distribution agreement for NMP22 Test Kit.